ZNF625 Antibody (N-term) Blocking Peptides
- Known as:
- ZNF625 Antibody (N-terminus) Blocking Peptides
- Catalog number:
- BP11499a
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- ZNF625 Antibody (N-term) Blocking Peptides
Related genes to: ZNF625 Antibody (N-term) Blocking Peptides
- Gene:
- ZNF625 NIH gene
- Name:
- zinc finger protein 625
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2004-04-22
- Date modifiied:
- 2016-04-25
Related products to: ZNF625 Antibody (N-term) Blocking Peptides
Related articles to: ZNF625 Antibody (N-term) Blocking Peptides
- Kidney transplantation remains the gold standard of treatment for end-stage renal disease (ESRD), with improved patient outcomes compared with dialysis. Epigenome-Wide Association Analysis (EWAS) of DNA methylation may identify markers that contribute to an individual's risk of adverse transplant outcomes, yet only a limited number of EWAS have been conducted in kidney transplant recipients. This EWAS aimed to interrogate the methylation profile of a kidney transplant recipient cohort with minimal posttransplant complications, exploring differences in samples pretransplant and posttransplant. - Source: PubMed
Publication date: 2022/11/14
Smyth Laura JKerr Katie RKilner JillMcGill Áine EMaxwell Alexander PMcKnight Amy Jayne - Patients with adenomatous polyposis syndromes such as familial adenomatous polyposis are at higher risk of colorectal cancer, hence continuous management is necessary. However, little is known about the etiology of patients with numerous laterally spreading tumors (LSTs), or how genetic alterations uniquely influence LSTs in colorectal carcinogenesis. The present case report investigated a woman with >150 non-granular type LSTs (LST-NG) and one sigmoid colon cancer. After subtotal colectomy via ileorectal anastomosis, genetic and epigenetic analyses were conducted by comparing the profiles of the patient's normal colonic mucosa, four LST-NG lesions and a cancer lesion. Using customized multigene panel testing, no pathogenic germline mutations were detected, including APC regulator of WNT signaling pathway, but identified a somatic pathogenic variant of in one LST-NG lesion, and both and F-box and WD repeat domain containing 7 somatic mutations in the cancer. Comprehensive genome-wide methylation analysis showed that CpG island promoters at zinc finger protein 625, LON peptidase N-terminal domain and ring finger 2, WD repeat domain 17 and syndecan 2 were methylated in both LST-NG and cancer, which may contribute to colorectal tumorigenesis as early as the LST-NG phase. - Source: PubMed
Publication date: 2022/11/17
Iwaizumi MoriyaTaniguchi TerumiKurachi KiyotakaOsawa SatoshiSugimoto KenBaba SatoshiSugimura HaruhikoMaekawa Masato - DNA methylation is a potential tumor marker for several cancers, including colorectal cancer (CRC), because of its heritable and stable characteristics. - Source: PubMed
Publication date: 2014/12/04
Lin Pei-ChingLin Jen-KouLin Chien-HsingLin Hung-HsinYang Shung-HaurJiang Jeng-KaiChen Wei-ShoneChou Chih-ChiTsai Shih-FengChang Shih-Ching